Clinical trial NCT01590472 - References

Mesothelioma — Do Your Genes Put You at a Higher Risk of Developing Mesothelioma

Citation(s)

•   Amundadottir LT, Sulem P, Gudmundsson J, Helgason A, Baker A, Agnarsson BA, Sigurdsson A, Benediktsdottir KR, Cazier JB, Sainz J, Jakobsdottir M, Kostic J, Magnusdottir DN, Ghosh S, Agnarsson K, Birgisdottir B, Le Roux L, Olafsdottir A, Blondal T, Andresdottir M, Gretarsdottir OS, Bergthorsson JT, Gudbjartsson D, Gylfason A, Thorleifsson G, Manolescu A, Kristjansson K, Geirsson G, Isaksson H, Douglas J, Johansson JE, Bälter K, Wiklund F, Montie JE, Yu X, Suarez BK, Ober C, Cooney KA, Gronberg H, Catalona WJ, Einarsson GV, Barkardottir RB, Gulcher JR, Kong A, Thorsteinsdottir U, Stefansson K
  A common variant associated with prostate cancer in European and African populations. Nat Genet. 2006 Jun;38(6):652-8. Epub 2006 May 7.
•   Asbestos, asbestosis, and cancer: the Helsinki criteria for diagnosis and attribution
  Scand J Work Environ Health. 1997 Aug;23(4):311-6. Review.
•   Baris I, Simonato L, Artvinli M, Pooley F, Saracci R, Skidmore J, Wagner C
  Epidemiological and environmental evidence of the health effects of exposure to erionite fibres: a four-year study in the Cappadocian region of Turkey. Int J Cancer. 1987 Jan 15;39(1):10-7.
•   Baris YI, Sahin AA, Ozesmi M, Kerse I, Ozen E, Kolacan B, Altinörs M, Göktepeli A
  An outbreak of pleural mesothelioma and chronic fibrosing pleurisy in the village of Karain/Urgüp in Anatolia. Thorax. 1978 Apr;33(2):181-92.
•   Becklake MR, Toyota B, Stewart M, Hanson R, Hanley J
  Lung structure as a risk factor in adverse pulmonary responses to asbestos exposure. A case-referent study in Quebec chrysotile miners and millers. Am Rev Respir Dis. 1983 Sep;128(3):385-8.
•   Berry G, Wagner JC
  Effect of age at inoculation of asbestos on occurrence of mesotheliomas in rats. Int J Cancer. 1976 Apr 15;17(4):477-83.
•   Bertazzi PA
  Descriptive epidemiology of malignant mesothelioma. Med Lav. 2005 Jul-Aug;96(4):287-303. Review.
•   Bocchetta M, Di Resta I, Powers A, Fresco R, Tosolini A, Testa JR, Pass HI, Rizzo P, Carbone M
  Human mesothelial cells are unusually susceptible to simian virus 40-mediated transformation and asbestos cocarcinogenicity. Proc Natl Acad Sci U S A. 2000 Aug 29;97(18):10214-9.
•   Boezen HM
  Genome-wide association studies: what do they teach us about asthma and chronic obstructive pulmonary disease? Proc Am Thorac Soc. 2009 Dec;6(8):701-3. doi: 10.1513/pats.200907-058DP. Review.
•   Centers for Disease Control and Prevention (CDC)
  Malignant mesothelioma mortality--United States, 1999-2005. MMWR Morb Mortal Wkly Rep. 2009 Apr 24;58(15):393-6.
•   Cerhan JR, Ansell SM, Fredericksen ZS, Kay NE, Liebow M, Call TG, Dogan A, Cunningham JM, Wang AH, Liu-Mares W, Macon WR, Jelinek D, Witzig TE, Habermann TM, Slager SL
  Genetic variation in 1253 immune and inflammation genes and risk of non-Hodgkin lymphoma. Blood. 2007 Dec 15;110(13):4455-63. Epub 2007 Sep 7.
•   Dianzani I, Gibello L, Biava A, Giordano M, Bertolotti M, Betti M, Ferrante D, Guarrera S, Betta GP, Mirabelli D, Matullo G, Magnani C
  Polymorphisms in DNA repair genes as risk factors for asbestos-related malignant mesothelioma in a general population study. Mutat Res. 2006 Jul 25;599(1-2):124-34. Epub 2006 Mar 27.
•   Freedman ML, Haiman CA, Patterson N, McDonald GJ, Tandon A, Waliszewska A, Penney K, Steen RG, Ardlie K, John EM, Oakley-Girvan I, Whittemore AS, Cooney KA, Ingles SA, Altshuler D, Henderson BE, Reich D
  Admixture mapping identifies 8q24 as a prostate cancer risk locus in African-American men. Proc Natl Acad Sci U S A. 2006 Sep 19;103(38):14068-73. Epub 2006 Aug 31.
•   Gerger A, Hofmann G, Langsenlehner U, Renner W, Weitzer W, Wehrschütz M, Wascher T, Samonigg H, Krippl P
  Integrin alpha-2 and beta-3 gene polymorphisms and colorectal cancer risk. Int J Colorectal Dis. 2009 Feb;24(2):159-63. doi: 10.1007/s00384-008-0587-9. Epub 2008 Oct 3.
•   Gudmundsson J, Sulem P, Manolescu A, Amundadottir LT, Gudbjartsson D, Helgason A, Rafnar T, Bergthorsson JT, Agnarsson BA, Baker A, Sigurdsson A, Benediktsdottir KR, Jakobsdottir M, Xu J, Blondal T, Kostic J, Sun J, Ghosh S, Stacey SN, Mouy M, Saemundsdottir J, Backman VM, Kristjansson K, Tres A, Partin AW, Albers-Akkers MT, Godino-Ivan Marcos J, Walsh PC, Swinkels DW, Navarrete S, Isaacs SD, Aben KK, Graif T, Cashy J, Ruiz-Echarri M, Wiley KE, Suarez BK, Witjes JA, Frigge M, Ober C, Jonsson E, Einarsson GV, Mayordomo JI, Kiemeney LA, Isaacs WB, Catalona WJ, Barkardottir RB, Gulcher JR, Thorsteinsdottir U, Kong A, Stefansson K
  Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet. 2007 May;39(5):631-7. Epub 2007 Apr 1.
•   Gudmundsson J, Sulem P, Steinthorsdottir V, Bergthorsson JT, Thorleifsson G, Manolescu A, Rafnar T, Gudbjartsson D, Agnarsson BA, Baker A, Sigurdsson A, Benediktsdottir KR, Jakobsdottir M, Blondal T, Stacey SN, Helgason A, Gunnarsdottir S, Olafsdottir A, Kristinsson KT, Birgisdottir B, Ghosh S, Thorlacius S, Magnusdottir D, Stefansdottir G, Kristjansson K, Bagger Y, Wilensky RL, Reilly MP, Morris AD, Kimber CH, Adeyemo A, Chen Y, Zhou J, So WY, Tong PC, Ng MC, Hansen T, Andersen G, Borch-Johnsen K, Jorgensen T, Tres A, Fuertes F, Ruiz-Echarri M, Asin L, Saez B, van Boven E, Klaver S, Swinkels DW, Aben KK, Graif T, Cashy J, Suarez BK, van Vierssen Trip O, Frigge ML, Ober C, Hofker MH, Wijmenga C, Christiansen C, Rader DJ, Palmer CN, Rotimi C, Chan JC, Pedersen O, Sigurdsson G, Benediktsson R, Jonsson E, Einarsson GV, Mayordomo JI, Catalona WJ, Kiemeney LA, Barkardottir RB, Gulcher JR, Thorsteinsdottir U, Kong A, Stefansson K
  Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat Genet. 2007 Aug;39(8):977-83. Epub 2007 Jul 1.
•   Hirschhorn JN, Daly MJ
  Genome-wide association studies for common diseases and complex traits. Nat Rev Genet. 2005 Feb;6(2):95-108. Review.
•   Kamp DW, Weitzman SA
  Asbestosis: clinical spectrum and pathogenic mechanisms. Proc Soc Exp Biol Med. 1997 Jan;214(1):12-26. Review.
•   Landi S, Gemignani F, Neri M, Barale R, Bonassi S, Bottari F, Canessa PA, Canzian F, Ceppi M, Filiberti R, Ivaldi GP, Mencoboni M, Scaruffi P, Tonini GP, Mutti L, Puntoni R
  Polymorphisms of glutathione-S-transferase M1 and manganese superoxide dismutase are associated with the risk of malignant pleural mesothelioma. Int J Cancer. 2007 Jun 15;120(12):2739-43.
•   Langsenlehner U, Renner W, Yazdani-Biuki B, Eder T, Wascher TC, Paulweber B, Clar H, Hofmann G, Samonigg H, Krippl P
  Integrin alpha-2 and beta-3 gene polymorphisms and breast cancer risk. Breast Cancer Res Treat. 2006 May;97(1):67-72.
•   Neragi-Miandoab S
  Multimodality approach in management of malignant pleural mesothelioma. Eur J Cardiothorac Surg. 2006 Jan;29(1):14-9. Epub 2005 Dec 15. Review.
•   O'Donnell CJ, Nabel EG
  Cardiovascular genomics, personalized medicine, and the National Heart, Lung, and Blood Institute: part I: the beginning of an era. Circ Cardiovasc Genet. 2008 Oct;1(1):51-7. doi: 10.1161/CIRCGENETICS.108.813337. Review.
•   Ohar J, Sterling DA, Bleecker E, Donohue J
  Changing patterns in asbestos-induced lung disease. Chest. 2004 Feb;125(2):744-53.
•   Ohar JA, Ampleford EJ, Howard SE, Sterling DA
  Identification of a mesothelioma phenotype. Respir Med. 2007 Mar;101(3):503-9. Epub 2006 Aug 21. Erratum in: Respir Med. 2008 Dec;102(12):1844.
•   Ohashi R, Tajima K, Takahashi F, Cui R, Gu T, Shimizu K, Nishio K, Fukuoka K, Nakano T, Takahashi K
  Osteopontin modulates malignant pleural mesothelioma cell functions in vitro. Anticancer Res. 2009 Jun;29(6):2205-14.
•   Paul S, Neragi-Miandoab S, Jaklitsch MT
  Preoperative assessment and therapeutic options for patients with malignant pleural mesothelioma. Thorac Surg Clin. 2004 Nov;14(4):505-16, ix. Review.
•   Rai AJ, Flores RM, Mathew A, Gonzalez-Espinoza R, Bott M, Ladanyi M, Rusch V, Fleisher M
  Soluble mesothelin related peptides (SMRP) and osteopontin as protein biomarkers for malignant mesothelioma: analytical validation of ELISA based assays and characterization at mRNA and protein levels. Clin Chem Lab Med. 2010 Feb;48(2):271-8. doi: 10.1515/CCLM.2010.066.
•   Robinson BW, Lake RA
  Advances in malignant mesothelioma. N Engl J Med. 2005 Oct 13;353(15):1591-603. Review.
•   Robinson BW, Musk AW, Lake RA
  Malignant mesothelioma. Lancet. 2005 Jul 30-Aug 5;366(9483):397-408. Review.
•   Sluis-Cremer GK
  Asbestos disease at low exposures after long residence times. Ann N Y Acad Sci. 1991 Dec 31;643:182-93.
•   Smith DD
  Women and mesothelioma. Chest. 2002 Dec;122(6):1885-6.
•   Spirtas R, Heineman EF, Bernstein L, Beebe GW, Keehn RJ, Stark A, Harlow BL, Benichou J
  Malignant mesothelioma: attributable risk of asbestos exposure. Occup Environ Med. 1994 Dec;51(12):804-11.
•   Tajima K, Ohashi R, Sekido Y, Hida T, Nara T, Hashimoto M, Iwakami S, Minakata K, Yae T, Takahashi F, Saya H, Takahashi K
  Osteopontin-mediated enhanced hyaluronan binding induces multidrug resistance in mesothelioma cells. Oncogene. 2010 Apr 1;29(13):1941-51. doi: 10.1038/onc.2009.478. Epub 2010 Jan 18.
•   Wheatley-Price P, Yang B, Patsios D, Patel D, Ma C, Xu W, Leighl N, Feld R, Cho BC, O'Sullivan B, Roberts H, Tsao MS, Tammemagi M, Anraku M, Chen Z, de Perrot M, Liu G
  Soluble mesothelin-related Peptide and osteopontin as markers of response in malignant mesothelioma. J Clin Oncol. 2010 Jul 10;28(20):3316-22. doi: 10.1200/JCO.2009.26.9944. Epub 2010 May 24.
•   Xu L, Flynn BJ, Ungar S, Pass HI, Linnainmaa K, Mattson K, Gerwin BI
  Asbestos induction of extended lifespan in normal human mesothelial cells: interindividual susceptibility and SV40 T antigen. Carcinogenesis. 1999 May;20(5):773-83.

Consortium for the Sharing of Germ Line DNA and Tissue From Subjects With Mesothelioma

Details for clinical trial NCT01590472